Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “PARP”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Ended earlyNCT02500901
What this trial is testing

Enzalutamide and Niraparib in the Treatment of Metastatic Castrate-Resistant Prostate Cancer (CRPC)

Who this might be right for
Metastatic Prostate Cancer
Paul Mathew, MD 2
Not applicableStudy completedNCT04917744
What this trial is testing

Metabolite Levels in Ovarian Cancer Patients Receiving Maintenance PARP Inhibitors

Who this might be right for
Ovarian Carcinoma
Mayo Clinic 5
Testing effectiveness (Phase 2)Ended earlyNCT02034916
What this trial is testing

A Phase 2, 2-Stage, 2-Cohort Study of Talazoparib (BMN 673), in Locally Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (ABRAZO Study)

Who this might be right for
Breast NeoplasmsBRCA 1 Gene MutationBRCA 2 Gene Mutation
Pfizer 84
Early research (Phase 1)Study completedNCT01776437
What this trial is testing

Study of BMN 673, a PARP Inhibitor, in Healthy Adult Male Volunteers

Who this might be right for
Human Volunteers
Pfizer 18
Testing effectiveness (Phase 2)Looking for participantsNCT06844383
What this trial is testing

Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate or Darolutamide

Who this might be right for
Prostate Cancer (Adenocarcinoma)mCRPC (Metastatic Castration-resistant Prostate Cancer)
Prostate Cancer Clinical Trials Consortium 126
Early research (Phase 1)Active Not RecruitingNCT06421935
What this trial is testing

M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501)

Who this might be right for
Advanced Solid Tumor
EMD Serono Research & Development Institute, Inc. 60
Testing effectiveness (Phase 2)Active Not RecruitingNCT01012817
What this trial is testing

Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer

Who this might be right for
Metastatic Malignant Solid NeoplasmRecurrent Fallopian Tube CarcinomaRecurrent Ovarian Carcinoma+2 more
National Cancer Institute (NCI) 88
Testing effectiveness (Phase 2)Study completedNCT02354131
What this trial is testing

Niraparib Versus Niraparib-bevacizumab Combination in Women With Platinum-sensitive Epithelial Ovarian Cancer

Who this might be right for
Ovarian Cancer
Nordic Society of Gynaecological Oncology - Clinical Trials Unit 108
Early research (Phase 1)Ended earlyNCT03944902
What this trial is testing

CB-839 in Combination With Niraparib in Platinum Resistant BRCA -Wild-type Ovarian Cancer Patients

Who this might be right for
Ovarian CancerResistant BRCA Wild-Type Ovarian Cancer
University of Alabama at Birmingham 1
Early research (Phase 1)Active Not RecruitingNCT04170153
What this trial is testing

Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)

Who this might be right for
Metastatic or Locally Advanced Unresectable Solid Tumors
EMD Serono Research & Development Institute, Inc. 161
Very early researchStudy completedNCT03911453
What this trial is testing

Window of Opportunity Trial, PARP Inhibitor Rucaparib Affect on PD-L1 Expression in Triple Negative Breast Tumors

Who this might be right for
Breast Cancer
University of Arizona 20
Not applicableLooking for participantsNCT05242744
What this trial is testing

FTT PET/CT in Metastatic Prostate Cancer

Who this might be right for
Prostate Cancer Metastatic
Abramson Cancer Center at Penn Medicine 30
Testing effectiveness (Phase 2)Study completedNCT01618136
What this trial is testing

An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors

Who this might be right for
Malignant Solid TumourOvarian CancerTriple Negative Breast Cancer+2 more
Eisai Limited 41
Not applicableUnknownNCT05763472
What this trial is testing

Breast Cancer After Ovarian Cancer During and/or After Therapy: Genomic Evaluation

Who this might be right for
BRCA-Associated Breast Carcinoma
Fondazione Policlinico Universitario Agostino Gemelli IRCCS 10
Testing effectiveness (Phase 2)Study completedNCT03404960
What this trial is testing

Niraparib + Ipilimumab or Nivolumab in Progression Free Pancreatic Adenocarcinoma After Platinum-Based Chemotherapy

Who this might be right for
Pancreatic Adenocarcinoma
University of Pennsylvania 104
Large-scale testing (Phase 3)Study completedNCT01945775
What this trial is testing

A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study)

Who this might be right for
Breast NeoplasmsBRCA 1 Gene MutationBRCA 2 Gene Mutation
Pfizer 431
Testing effectiveness (Phase 2)WithdrawnNCT06116578
What this trial is testing

Study Evaluating Pembrolizumab +/- Olaparib in TLS Positive Selected Resectable STS Followed by Adjuvant Pembrolizumab

Who this might be right for
Cancer
Gustave Roussy, Cancer Campus, Grand Paris
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07339553
What this trial is testing

Clinical Study of EZH2 Inhibitor Combined With PARP Inhibitor in the Treatment of Patients With Advanced or Recurrent Epithelial Ovarian Cancer.

Who this might be right for
OvariancancerPlatinum-sensitive Recurrent
Peking University Third Hospital 30
Testing effectiveness (Phase 2)Study completedNCT05455424
What this trial is testing

Niraparib Efficacy in Patient With Unresectable Mesothelioma

Who this might be right for
Mesothelioma, Malignant
University Hospital Southampton NHS Foundation Trust 88
Early research (Phase 1)Active Not RecruitingNCT03162627
What this trial is testing

Selumetinib and Olaparib in Solid Tumors

Who this might be right for
Malignant Neoplasm of BreastMalignant Neoplasms of Digestive OrgansMalignant Neoplasms of Female Genital Organs+2 more
M.D. Anderson Cancer Center 90
Next Page